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ttp://dx.doi.org/10.1016/j.jmoldx.2014.07.001Loss of function variants in the PCDH15 gene can cause Usher syndrome type 1F, an autosomal recessive
disease associated with profound congenital hearing loss, vestibular dysfunction, and retinitis pigmentosa.
The Ashkenazi Jewish population has an increased incidence of Usher syndrome type 1F (founder variant
p.Arg245X accounts for 75% of alleles), yet the variant spectrum in a panethnic population remains un-
determined. We sequenced the coding region and intron-exon borders of PCDH15 using next-generation
DNA sequencing technology in approximately 14,000 patients from fertility clinics. More than 600
unique PCDH15 variants (single nucleotide changes and small indels) were identiﬁed, including previously
described pathogenic variants p.Arg3X, p.Arg245X (ﬁve patients), p.Arg643X, p.Arg929X, and p.Arg1106X.
Novel truncating variants were also found, including one in the N-terminal extracellular domain
(p.Leu877X), but all other novel truncating variants clustered in the exon 33 encoded C-terminal cyto-
plasmic domain (52 patients, 14 variants). One variant was observed predominantly in African Americans
(carrier frequency of 2.3%). The high incidence of truncating exon 33 variants indicates that they are
unlikely to cause Usher syndrome type 1F even though many remove a large portion of the gene. They may
be tolerated because PCDH15 has several alternate cytoplasmic domain exons and differentially spliced
isoforms may function redundantly. Effects of some PCDH15 truncating variants were addressed by
deep sequencing of a panethnic population. (J Mol Diagn 2014, 16: 673e678; http://dx.doi.org/10.1016/
j.jmoldx.2014.07.001)Supported by Good Start Genetics, Inc.
Disclosures: At the time of manuscript submission, all authors were
employees of Good Start Genetics, Inc. All full-time employees have stock
options in the company and hence are potential future shareholders in Good
Start Genetics, Inc.
Current address of C.J.K., Department of Bioinformatics Research,
National Marrow Donor Program, Minneapolis, MN.Usher syndrome is an incurable disease that is diagnosed in
approximately 4 of every 100,000 infants born in the United
States and other developed countries. There are three types of
Usher syndrome (types 1, 2, and 3) that differ in the genetic
cause and clinical proﬁle. Types 1 and 2 account for approx-
imately 95% of Usher syndrome cases. Children with type
1 are almost totally deaf at birth, have severe balance problems,
and usually develop severe vision problems before 10 years of
age. There is currently no cure, and treatment focuses on
helping the child adapt to the symptoms. Usher syndrome type
1 includes a variety of subtypes and can be caused by variants
in any one of several different genes, includingMYO7A (type
1B), USH1C (type 1C), CDH23 (type 1D), PCDH15 (type
1F), and SANS (type 1G). Type 1F (Online Mendelian Inher-
itance of Man no. 602083) is inherited in an autosomalstigative Pathology
.recessive manner and is of interest because of the increased
prevalence in individuals of Ashkenazi Jewish ancestry, yet
outside this population it is believed to be rare. Aside
from Usher syndrome, nonsyndromic deafness has also
been reported to be associated with PCHD15 variants on
some occasions (http://www.nidcd.nih.gov/health/hearing/
pages/usher.aspx, last accessed March 12, 2014).
Perreault-Micale et alProtocadherin-15 (PCDH15) is an integral membrane pro-
tein and a member of the cadherin superfamily of proteins that
mediate calcium-dependent cell to cell adhesion. The gene
structure is complicated, with a large number of exons and
alternative splicing generating multiple isoforms. The cyto-
plasmic domain (CD) 1 isoform, also called A or CD1-1, is
typically chosen as the canonical sequence because of its
prevalence, length, and similarity to orthologs. It is composed
of 1955 amino acids, including (from N- to C-terminus) a
signal peptide, 11 highly conserved cadherin calcium-binding
domains, or ectodomains, a transmembrane domain, and
an intracellular or CD. The C-terminal CD is very large and
includes approximately 30% of the entire protein (amino
acids 1398 to 1955, UniProt, http://www.uniprot.org/uniprot,
accession number Q96QU1).
In hair cells of the inner ear, PCDH15 is a major
component of the tip links. Tip links are complexes that
consist of PCDH15 homodimers that interact with cadherin
23 (CDH23) homodimers.1 The exact roles of PCDH15 and
CDH23 in mechanosensory transduction in the inner ear are
only beginning to be elucidated, although it is clear that they
are vital components in the function and structure of the tip
link.1e3 Animal studies have been pivotal in deﬁning the
importance of the tip link interface and PCDH15 in hearing.
The Ames waltzer mouse model provided the ﬁrst evidence
that PCDH15 is required for normal inner ear function.4,5
Further genetic studies extended these ﬁndings to impli-
cate speciﬁc amino acids. Noddy mouse homozygotes with
an isoleucine-to-asparagine (p.Ile108Asn) variant in the
ectodomain 1 repeat of PCDH15 lack inner ear function.6 In
zebraﬁsh, the PCDH15 gene has been found to be dupli-
cated, with one gene required for proper inner ear function
and the other required by the developing eye.7 The crucial
role that PCDH15 plays in maintaining normal retinal and
cochlear function explains why loss of function variants in
the PCDH15 gene can cause the variety of mechanosensory
defects that deﬁne Usher syndrome type 1F.4,5,8
The accurate identiﬁcation of Usher syndrome type 1F
carriers helps prospective parents make better informed
reproductive decisions and serves to help reduce the rate at
which children are born with this debilitating condition. The
available clinical carrier screening tests traditionally consist
of a limited genotyping panel that contains targeted variant
sets aimed toward speciﬁc populations, such as the Ashke-
nazi Jewish population. We have developed the ﬁrst next-
generation screening (NGS)ebased clinical carrier screening
method and have successfully implemented it during the past
several years.9,10 Some of the major advantages of this
technology are that it is able to survey entire genes and detect
more potential disease-causing variants than limited geno-
typing panels, including novel variants, and that it can be
used in an ethnically independent manner. One can now
assess the carrier status and variant spectrum in a broader
range of patients who belong to a variety of ethnicities.
The goal of this study was to determine the variant spectrum
of Usher syndrome type 1F in a panethnic population. In the674Ashkenazi Jewish population, the founder variant, p.Arg245X,
accounts for approximately 75%of alleles (carrier frequency of
0.79% to 2.48%),11 but allele frequencies in other populations
have not yet been determined. We uncovered an unusual
cluster of novel truncating variants in exon 33 during our
investigation in a large and ethnically diverse fertility patient
population using NGS of PCDH15. We describe this vari-
ability and speculate that many of these changes are unlikely to
be responsible for disease based on a variety of criteria, such as
allele frequency, protein structure, and isoform variability or
redundancy.
Materials and Methods
Study participants included 14,264 patients referred by
fertility clinics across the United States for carrier screening.
Informed consent for research was obtained from all partic-
ipants. Seventy-one percent of patients also reported
ethnicity, country of origin, or a combination of both. For the
purpose of this study, we used only major categories: Asian,
African American, Ashkenazi Jewish, Caucasian (including
Mediterranean and French Canadian), Hispanic, and other
(all that could not be assigned to one of the major categories).
NGS Procedure
The NGS protocol used has been previously described.9
Brieﬂy, this procedure involves multiplex target capture
using tiled, molecular inversion probes followed by PCR-
mediated incorporation of patient-speciﬁc molecular barcodes
and Illumina sequencing adapters. The products (representing
the coding region and intron-exon borders of the PCDH15
gene) were then sequenced using Illumina (San Diego, CA)
Hiseq2000 and 2500 instruments. Data were processed as
described using a combination of open-source and internally
developed tools for sample demultiplexing, short read assem-
bly and alignment, genotype calling, and functional annotation.
Low quality (depth <50 and strand bias >0) calls and ho-
mozygous reference positions were ﬁltered. Previously
described alleles were identiﬁed using an in-house developed
database of PCDH15 gene variants.
Sanger Sequencing for Conﬁrmation of Variants
PCR primers were developed for each region of interest.
Brieﬂy, 30 mL reactions were conducted with 100 ng of
genomic DNA, 1 U of AmpliTaq Gold (Applied Biosystems,
Foster City, CA), and 1 mmol of each PCR primer in a PCR
mix that contained 5% dimethyl sulfoxide (v/v), 1 mol/L
betaine, 2.5 mmol/L magnesium chloride, 1 mmol/L dNTPs
(total), and 1 GeneAmp PCR Gold Buffer (Applied Bio-
Systems). Cycling conditions were as follows: 95C for 10
minutes, 30 (95C for 30 seconds, 60C for 30 seconds, and
72C for 30 seconds), 72C for 10 minutes, and 8C forever.
PCR primers used were as described by Jones et al,12 except
M13 tails were removed. PCR products were puriﬁed withjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 The ethnic distribution of the study population. The study
group comprised 14,264 patients referred by fertility clinics in the
United States for carrier screening. Ethnicity was self-reported. The raw
numbers of patients in each ethnic group are shown in parenthesis.
Other refers to all patients who could not be assigned to one of the
major categories.
PCDH15 VariantsAMPure Beads (Beckman Coulter, Pasadena, CA), and chain
termination bidirectional Sanger sequencing was performed on
anABI 3730xl DNA analyzer (Applied Biosystems) according
to standard protocols. Data were analyzed using Mutation
Surveyor version 4.0.9 (SoftGenetics, State College, PA).Table 1 PCDH15 Truncating Variants Identiﬁed in This Study
cDNA name
Protein
name Of note
No. of
patients (MAFs
c.7C>T p.Arg3X 1 (0.0035)
c.733C>T p.Arg245X Ashkenazi
Jewish Founder
5 (0.0175)
c.1927C>T p.Arg643X 1 (0.0035)
c.2630T>A p.Leu877X Novel 1 (0.0035)
c.2785C>T p.Arg929X 1 (0.0035)
c.3316C>T p.Arg1106X 1 (0.0035)
c.4548_4551dupATCT Novel 1 (0.0035)
c.4599_4600dupAA Novel 1 (0.0035)
c.4681_4684dupAAGT Novel 3 (0.0105)
c.4831_4834dupAACA Novel 33 (0.1157)
c.4902delA Novel 1 (0.0035)
c.4907_4908delAA Novel 1 (0.0035)
c.4937_4940dupTGAT Novel 1 (0.0035)
c.4945G>T p.Gly1649X Novel 2 (0.0070)
c.4970_4971delCT Novel 1 (0.0035)
c.5573_5576dupTTAA Novel 4 (0.0140)
c.5626C>T p.Gln1876X Novel 1 (0.0035)
c.5630_5633delGAGA Novel 1 (0.0035)
c.5721_5724delTCTA Novel 1 (0.0035)
c.5721_5724dupTCTA Novel 1 (0.0035)
The stop codon is at c.5868. Data from the ESP were examined for all truncating
and the percentage of overall MAFs (African Americans and European Americans) w
our data were also calculated for comparison (of 28,528 alleles). Three of the four
variants were detected; c.4369_4370insAAGTC (exon 33) and c.1915C>T, p.Gln63
the ESP data are denoted by a 0 under MAF ESP. ESP denotes duplications as inse
A, Asian; AA, African American; C, Caucasian; ESP, Exome Sequencing Project;
The Journal of Molecular Diagnostics - jmd.amjpathol.orgGene symbols are according to the HUGO Gene Nomen-
clature Committee suggestions (http://www.genenames.org,
last accessed March 12, 2014). Gene nomenclature follows
Human Genome Variation Society guidelines (http://www.
hgvs.org/mutnomen, last accessed March 12, 14). Protein de-
tails, such as isoform variability and expression patterns,
can be found in UniProt (http://www.uniprot.org/uniprot,
accession number Q96QU1). PCDH15 transcript is variant C,
NM_033056.3. Usher syndrome type 1F is Online Mendelian
Inheritance of Man no. 602083.Results
The study population consisted of 14,264 patients from
fertility clinics in the United States. These patients were
referred to us for carrier screening and represent an ethnically
diverse group that roughly approximates the population in
the United States today (http://www.census.gov/compendia/
statab/cats/population/estimates_and_projections_by_age_
sex_raceethnicity.html, last accessed July 22, 2014). The
ethnic distribution is depicted in Figure 1.
Overall, we found >600 unique variants (single-nucleo-
tide changes and small indels) in PCDH15 (transcript
variant CD-1, NM_033056.3) via NGS sequencing of the, %) Ethnicity In exon 33 Reference
No. of ESP
participants
(MAFs, %)
1 NP No 8 0
2 C, 2 NP, 1
Ashkenazi Jewish
No 17 5 (0.0384)
1 NP No 18 0
1 C No This study 0
1 C No 19 0
1 C No 20 0
1 NP Yes This study 0
1 AA Yes This study 0
2 AA, 1 H Yes This study 2 (0.0160)
24 AA, 7 NP, 2 H Yes This study 48 (0.3849)
1 A Yes This study 0
1 C Yes This study 10 (0.0799)
1 NP Yes This study 0
1 A, 1 NP Yes This study 0
1 O Yes This study 0
2 C, 2 NP Yes This study 0
1 A Yes This study 0
1 C Yes This study 0
1 A Yes This study 0
1 AA Yes This study 0
variants in transcript variant C, NM_033056.3. The number of participants
ere calculated from a range of 12,470 to 13,001 total alleles. The MAFs for
truncating variants in exon 33 and one of the two non-exon 33 truncating
9X (exon 15) were not detected. The variants detected that were absent in
rtions, for example, c.4831_4834dupAACA is named c.4834_4835insAACA.
H, Hispanic; MAF, minor allele frequency; NP, not provided; O, other.
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Figure 2 Schematic view of the location of PCDH15 truncating variants
found by exons (top) and protein domains (bottom). p.Arg245X is the
Ashkenazi Jewish founder variant. c.4257delA in exon 32 is the last
truncating variant reported in a patient with Usher syndrome type IF,13 but
this was not found in our patient cohort. Numbering refers to amino acids
as described in Uniprot (http://www.uniprot.org/uniprot, accession number
Q96QU1), NM_033056.3 (noncoding exon 1). Note that exons are not
drawn exactly to scale.
Perreault-Micale et alexons and intron-exon borders of 14,264 patients. Most of
the variants were benign or rare (allele frequency <0.1%),
previously unreported, and/or unclassiﬁed changes (data not
shown). Because rare missense variants are difﬁcult to
interpret without functional data, we focused our analysis on
novel truncating variants. A truncating variant is one that
occurs at a conserved donor or acceptor splice site (2
bases of intron), introduces a premature stop codon
(nonsense variant), or causes a shift in the reading frame
through insertion or deletion of bases and is therefore ex-
pected to disrupt gene and protein function.
Twenty unique truncating variants were found in 62
of the 14,264 patients analyzed. Fifteen of those changes
were veriﬁed by Sanger sequencing in at least one sample,
and for the other ﬁve variants, no samples were left for
conﬁrmation. Among all the variants identiﬁed were ﬁve
previously described PCDH15 pathogenic variants (p.Arg3X,
p.Arg245X, p.Arg643X, p.Arg929X, and p.Arg1106X). TheTable 2 PCDH15 Truncating Variant Carrier Frequencies Based on Thei
Ethnic group
No. of
individuals
Exons 1e32
No. of
variants
No. of
carriers
Carrier
frequency,
%
Carrie
freque
1 in X
All 14,264 6 10 0.070 1426
All without
c.4831_4834dupAACA
14,264
Caucasian 6569 4 5 0.076 1314
African American 1055 0 0 0.000
African American without
c.4831_4834dupAACA
1055
676Ashkenazi Jewish founder variant, p.Arg245X, was present in
ﬁve patients, and p.Arg3X, p.Arg643X, p.Arg929X, and
p.Arg1106X were found in one patient each (Table 1).
Fifteen of the twenty truncating variants identiﬁed were
novel. Notably, all the novel truncating variants mapped to
exon 33, except for 1 variant (Table 1 and Figure 2). The
exception is p.Leu877X, which is located in exon 20 and was
found in 1 patient. This region of the gene encodes the
N-terminal extracellular domain. Exon 33 constitutes themajor
part of the C-terminal CD in transcript variant C. Even though
the 500 amino acids encoded by this exon account for just
>25% of the protein, the frequency of truncating variants is
disproportionate compared with all the other exons (52 of 62 in
total) (Table 2). Moreover, approximately half of the patients
with variants in exon 33 were African Americans, yet no Af-
rican Americans had any variants in exons 1 to 32. Also sur-
prising was that one of the variants, c.4831_4834dupAACA,
was observed 33 times, and 24 carriers of this duplication
were self-reported African Americans (of 1055 African
Americans in our study population). This variant was also
found at the same frequency (1.13% versus 1.14% in our
study) in the African American cohort of the Exome
Sequencing Project (ESP; http://evs.gs.washington.edu/
EVS, last accessed March 12, 2014). In total, the ESP data
contained six unique PCDH15 truncating variants (tran-
script variant CD-1, NM_033056.3) that included four in
exon 33 (three of which we have also detected) and two in
exons other than 33 (one of which we have also detected).
The fact that ESP data reveal twice as many unique trun-
cating variants in exon 33 (four variants) than in all the other
32 exons (two variants) indicates that the frequency of
truncating variants by domains is roughly similar to ours.
We compared the minor allele frequencies (MAFs) reported
in the ESP data to our MAFs for four truncating variants that
were contained in the ESP and our data sets, and the MAFs
were in very close agreement with each other (Table 1).
Table 2 presents PCDH15 variant carrier frequencies
calculated for all known pathogenic and novel truncating
variants, depending on their position. The results indicate
high carrier frequencies if exon 33 variants are included in
the allele count and carrier frequencies much closer to ther Location and Patient’s Ethnic Group
Exon 33 Exons 1e33
r
ncy, No. of
variants
No. of
carriers
Carrier
frequency,
%
Carrier
frequency,
1 in X
Carrier
frequency,
%
Carrier
frequency,
1 in X
14 52 0.365 274 0.435 230
13 19 0.133 751 0.210 475
3 4 0.061 1642 0.137 730
4 28 2.645 38 2.654 38
3 4 0.379 264 0.379 264
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PCDH15 Variantsnumber expected for Usher syndrome if only variants in the
ﬁrst 32 exons are included.Discussion
We describe the distribution of known and potentially
pathogenic PCDH15 truncating variants in a panethnic
population. We found several known pathogenic truncating
variants (Table 1). The Ashkenazi Jewish founder variant
p.Arg245X was observed ﬁve times, although only once in
an individual explicitly identiﬁed as Ashkenazi Jewish. The
other four patients included two Caucasian patients and two
patients who did not provide their ethnicity (Table 1). It is
possible that patients of Ashkenazi Jewish descent described
themselves as Caucasians or that they are included in the
group of patients who did not report ethnicity. However, this
variant may not be restricted to individuals of Ashkenazi
Jewish descent and may be relatively common outside this
population. The other known variants occurred only once in
our study population, and at this point it is not clear what
their individual frequencies are or if there are speciﬁc eth-
nicities in which they are more frequent (Table 1).
The determination of the clinical signiﬁcance of the many
novel variants identiﬁed using NGS-based diagnostics tools
remains one of the most challenging aspects of whole gene
sequencing to date. In the absence of clinical and functional
data, we rely solely on sequence information to classify the
variants uncovered. Computational methods for predicting
the effect of more subtle changes, such as missense variants,
small in-frame deletions, or variants potentially interfering
with splicing, have not yet reached the sensitivity and
speciﬁcity required for clinical applications. However, var-
iants that lead to the loss of parts of a gene (and subse-
quently protein, if the mutant mRNA is translated), by
introducing a premature stop codon or deleting large parts of
the coding sequence, are generally thought to be pathogenic,
if they occur in genes where loss of function leads to disease
and they are observed in a patient. However, questions
remain on how much of a gene is essential and how much
can be missing without drastic effects, in particular if the
variant is observed in a healthy carrier.
The position of the most 30 truncating variant described in a
patient usually serves as a dividing line or demarcation point
between parts of the gene that can be considered required for full
function and those that may not be. For PCDH15, the variant
c.4257delA in exon 32 is the most 30 observed in a patient with
Usher syndrome 1F so far.13 Only one of the novel variants
described here, p.Leu877X, is upstream to c.4257delA and thus
can be predicted to cause disease with the high conﬁdence
required for carrier screening.However, approximately one-third
of the PCDH15 protein is encoded by DNA sequence down-
stream to the 30 most truncating variant previously described in a
patient with Usher syndrome type 1F, and this region encodes
nearly the entire CD, initially raising concern that our cutoff for
reporting novel pathogenic variants might be too conservative.The Journal of Molecular Diagnostics - jmd.amjpathol.orgFourteen novel truncating variants found in this study are
located in the CD (Table 1 and Figure 2). Despite the fact that
most of them are expected to remove>100 amino acids from
the C-terminal end, the combined frequency of those variants
argues against their pathogenicity. For example, unless the
allele distribution deviates from the Hardy-Weinberg equi-
librium for some reason, we would expect approximately 1 in
7750 African Americans to be homozygous for the variant
c.4831_4834dupAACA alone, a frequency that does not
support the notion that this variant underlies a severe
phenotype, such as Usher syndrome or nonsyndromic deaf-
ness. The incidence of all three types of Usher syndrome is
approximately 1 in 25,000, with types 1 and 2 accounting for
approximately 95% of this overall incidence. Therefore, a
projected frequency of 1 in 7750 African American homo-
zygotes, or affected individuals, would be in stark contrast
with the overall prevalence of any of the Usher syndrome
subtypes. The bias toward exon 33 for the location of trun-
cating variants persists even if c.4831_4834dupAACA is
removed from the analysis. In all individuals tested, 19 of the
30 alleles with truncating variants are located in the CD,
regardless of ethnicity. The trend is less pronounced but still
noticeable for Caucasians, in whom four of nine alleles were
found in exon 33 (Tables 1 and 2). Therefore, we concluded
that variants in this domain do not meet the requirements for
being reported as potentially pathogenic for population car-
rier screening purposes and should be evaluated with care in a
clinical context.
Our ﬁndings lead us to question how it is possible that
variants that cause the loss of a large part of the PCDH15
protein that encodes nearly an entire domain do not have
serious consequences. As mentioned earlier, PCDH15 has a
large number of isoforms. Hair cells express PCDH15-CD1,
PCDH15-CD2, and PCDH15-CD3 isoforms, which differ
mainly in their CDs and are the most well-studied and pre-
dominant biological isoforms.4,5,8,14,15 Transcript variant C
investigated in this study encodes a major CD1 isoform.Mouse
knockout studies by Webb et al16 report that knockout mice
lacking either CD1 or CD3 still retain tip links and hearing,
which suggests that these two isoforms can compensate for
each other. We speculate, based on these studies, that the
variants truncatingCD1 observed in this studymay be tolerated
because differentially spliced CD isoforms can also function
redundantly in humans. However, we cannot exclude the
possibility that these variants may contribute to a more subtle
hearing, vision, or, thus far unidentiﬁed, phenotype.
In conclusion, deep sequencing of PCDH15 reveals that
the spectrum of pathogenic variants in our panethnic study
population is still dominated by the Ashkenazi Jewish
founder variant, p.Arg245X, which accounts for almost half
the identiﬁed disease alleles. The other disease variants
appear to be rare. The unexpectedly high incidence of novel
truncating variants observed in exon 33 indicates that they
are not very likely to cause the severe phenotype associated
with Usher syndrome type 1F and need to be evaluated with
caution.677
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